Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy

European Journal of Clinical Pharmacology

Volumn 66, Issue 8, 2010, Pages 755-774

  Gervasini, Guillermo ^a   Benítez, Julio ^a   Carrillo, Juan Antonio ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Biomarkers; Personalized medicine; Pharmacogenetics; Therapeutic drug monitoring (TDM)

Indexed keywords

ABACAVIR; AMITRIPTYLINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; ARIPIPRAZOLE; CETUXIMAB; CLOMIPRAMINE; CLOZAPINE; DASATINIB; DULOXETINE; EFAVIRENZ; FLUOXETINE; FLUPHENAZINE; HALOPERIDOL; IMIPRAMINE; IMMUNOSUPPRESSIVE AGENT; IRINOTECAN; MARAVIROC; NEVIRAPINE; PHENYTOIN; PSYCHOTROPIC AGENT; RISPERIDONE; TAMOXIFEN; TRASTUZUMAB; UNINDEXED DRUG; VENLAFAXINE; WARFARIN;

BREAST CANCER; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL RESEARCH; COLORECTAL CANCER; DIARRHEA; DOCTOR PATIENT RELATION; DRUG COST; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG TOXICITY; ENVIRONMENTAL FACTOR; GENETIC ANALYSIS; GENETIC VARIABILITY; HEREDITY; HUMAN; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL INFORMATION; NEUROTOXICITY; NEUTROPENIA; PATIENT CARE; PHARMACOGENETICS; PHENOTYPE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; STANDARD; STUDY DESIGN;

DRUG MONITORING; DRUG THERAPY; GENETIC TESTING; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHENOTYPE; STANDARD OF CARE;

EID: 77955558089     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0857-7     Document Type: Review

References (187)

1. BB Spear M Heath-Chiozzi J Huff 2001 Clinical application of pharmacogenetics Trends Mol Med 7 201 204 1:CAS:528:DC%2BD3MXjvFygurs%3D 11325631
2. J Lazarou BH Pomeranz PN Corey 1998 Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies JAMA 279 1200 1205 1:STN:280:DyaK1c3hsFSnsQ%3D%3D 9555760
3. DR Nelson 2009 The cytochrome p450 homepage Hum Genomics 4 59 65 19951895
4. WE Evans MV Relling 1999 Pharmacogenomics: translating functional genomics into rational therapeutics Science 286 487 491 1:CAS:528: DyaK1MXmvVOhtL0%3D 10521338
5. KA Phillips DL Veenstra E Oren JK Lee W Sadee 2001 Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review JAMA 286 2270 2279 1:CAS:528:DC%2BD3MXosFCktro%3D 11710893
6. I Johansson E Lundqvist L Bertilsson ML Dahl F Sjoqvist M Ingelman-Sundberg 1993 Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine Proc Natl Acad Sci USA 90 11825 11829 1:CAS:528:DyaK2cXntVOrsA%3D%3D 7903454
7. L Bertilsson ML Dahl P Dalen A Al-Shurbaji 2002 Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs Br J Clin Pharmacol 53 111 122 1:CAS:528:DC%2BD38XhsVGru7o%3D 11851634
8. WH Chou FX Yan J de Leon J Barnhill T Rogers M Cronin M Pho V Xiao TB Ryder WW Liu C Teiling PJ Wedlund 2000 Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness J Clin Psychopharmacol 20 246 251 1:STN:280: DC%2BD3c3jtFagtg%3D%3D 10770465
9. F Sjoqvist E Eliasson 2007 The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants Clin Pharmacol Ther 81 899 902 1:STN:280:DC%2BD2s3pt1ChsQ%3D%3D 17392719
10. NT Hansen S Brunak RB Altman 2009 Generating genome-scale candidate gene lists for pharmacogenomics Clin Pharmacol Ther 86 183 189 1:CAS:528: DC%2BD1MXovFOrt7g%3D 19369935
11. FW Frueh S Amur P Mummaneni RS Epstein RE Aubert TM DeLuca RR Verbrugge GJ Burckart LJ Lesko 2008 Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use Pharmacotherapy 28 992 998 18657016
12. J de Leon SC Armstrong KL Cozza 2006 Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19 Psychosomatics 47 75 85 16384813
13. DA Flockhart T Skaar DS Berlin TE Klein AT Nguyen 2009 Clinically available pharmacogenomics tests Clin Pharmacol Ther 86 109 113 1:CAS:528:DC%2BD1MXnsFemtbY%3D 19369936
14. R Nowack J Andrassy M Fischereder M Unger 2009 Effects of dietary factors on drug transport and metabolism: the impact on dosage guidelines in transplant patients Clin Pharmacol Ther 85 439 443 1:CAS:528:DC%2BD1MXjtlSmurk%3D 19225452
15. S Caccia S Garattini L Pasina A Nobili 2009 Predicting the clinical relevance of drug interactions from pre-approval studies Drug Saf 32 1017 1039 1:CAS:528:DC%2BD1MXhsFWlu7%2FM 19810775
16. CB Nemeroff SH Preskorn CL Devane 2007 Antidepressant drug-drug interactions: clinical relevance and risk management CNS Spectr 12 1 13 17514084
17. L Urichuk TI Prior S Dursun G Baker 2008 Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions Curr Drug Metab 9 410 418 1:CAS:528:DC%2BD1cXotF2ntLg%3D 18537577
18. L Ekselius F Bengtsson L von Knorring 2000 Non-compliance with pharmacotherapy of depression is associated with a sensation seeking personality Int Clin Psychopharmacol 15 273 278 1:STN:280:DC%2BD3cvktlSguw%3D%3D 10993129
19. AJ McLachlan SN Hilmer DG Le Couteur 2009 Variability in response to medicines in older people: phenotypic and genotypic factors Clin Pharmacol Ther 85 431 433 1:CAS:528:DC%2BD1MXjtlSmur8%3D 19225449
20. ET Morgan 2009 Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics Clin Pharmacol Ther 85 434 438 1:CAS:528:DC%2BD1MXjtlSmurg%3D 19212314
21. ET Morgan KB Goralski M Piquette-Miller KW Renton GR Robertson MR Chaluvadi KA Charles SJ Clarke M Kacevska C Liddle TA Richardson R Sharma CJ Sinal 2008 Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer Drug Metab Dispos 36 205 216 1:CAS:528:DC%2BD1cXht1yktbw%3D 18218849
22. VD Schmith JF Foss 2008 Effects of inflammation on pharmacokinetics/ pharmacodynamics: increasing recognition of its contribution to variability in response Clin Pharmacol Ther 83 809 811 1:CAS:528:DC%2BD1cXlvFOrtbk%3D 18488052
23. BA Sproule CA Naranjo KE Brenmer PC Hassan 1997 Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence Clin Pharmacokinet 33 454 471 1:CAS:528:DyaK1cXjtlGqtA%3D%3D 9435993
24. M Thomas AA Boggs B DiPaula S Siddiqi 2010 Adverse drug reactions in hospitalized psychiatric patients Ann Pharmacother 44 819 825 20371749
25. JA Carrillo J Benitez 2000 Clinically significant pharmacokinetic interactions between dietary caffeine and medications Clin Pharmacokinet 39 127 153 1:CAS:528:DC%2BD3cXmvVemtrg%3D 10976659
26. SJ Davies S Eayrs P Pratt MS Lennard 2004 Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards Br J Clin Pharmacol 57 464 472 1:CAS:528:DC%2BD2cXjslGmsb4%3D 15025745
27. E Spina J de Leon 2007 Metabolic drug interactions with newer antipsychotics: a comparative review Basic Clin Pharmacol Toxicol 100 4 22 1:CAS:528:DC%2BD2sXivVOrsr8%3D 17214606
28. JA Carrillo AG Herraiz SI Ramos J Benitez 1998 Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients J Clin Psychopharmacol 18 311 316 1:CAS:528:DyaK1cXltFSms7k%3D 9690697
29. JA Carrillo SI Ramos AG Herraiz A Llerena JA Agundez R Berecz M Duran J Benitez 1999 Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients J Clin Psychopharmacol 19 494 499 1:CAS:528: DyaK1MXotVertbk%3D 10587283
30. M Christensen G Tybring K Mihara N Yasui-Furokori JA Carrillo SI Ramos K Andersson ML Dahl L Bertilsson 2002 Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19) Clin Pharmacol Ther 71 141 152 1:CAS:528:DC%2BD38XjtFChurw%3D 11907488
31. F Sjoqvist L Bertilsson 1984 Clinical pharmacology of antidepressant drugs: pharmacogenetics Adv Biochem Psychopharmacol 39 359 372 1:STN:280:DyaL2c3nslWhuw%3D%3D 6380229
32. C Hiemke 2008 Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry Eur J Clin Pharmacol 64 159 166 18196227
33. B Alexanderson DA Evans F Sjoqvist 1969 Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy Br Med J 4 764 768 1:STN:280:DyaE3c%2FmtlSrtQ%3D%3D 5391106
34. M Asberg B Cronholm F Sjoqvist D Tuck 1971 Relationship between plasma level and therapeutic effect of nortriptyline Br Med J 3 331 334 1:STN:280:DyaE3M3lt1WgsQ%3D%3D 5558186
35. P Baumann 1986 Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test Encephale 12 143 148 1:STN:280:DyaL2s%2FotVWktQ%3D%3D 3792273
36. P Baumann C Hiemke S Ulrich G Eckermann I Gaertner M Gerlach HJ Kuss G Laux B Muller-Oerlinghausen ML Rao P Riederer G Zernig Arbeitsge-meinschaft fur neuropsychopharmakologie und pharmakopsychiatrie 2004 The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry Pharmacopsychiatry 37 243 265 1:CAS:528:DC%2BD2MXpslCksw%3D%3D 15551191 (Pubitemid 39587052)
37. P Marquet A Rousseau 2008 Pharmacokinetics and therapeutic drug monitoring of anticancer agents Bull Cancer 95 903 909 1:CAS:528: DC%2BD1MXlvFSlsg%3D%3D 19004719
38. M Rotger A Telenti 2008 Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring? Eur J Clin Pharmacol 64 335 336 18188549
39. PE Wallemacq 2004 Therapeutic monitoring of immunosuppressant drugs. Where are we? Clin Chem Lab Med 42 1204 1211 1:CAS:528:DC%2BD2cXhtVGku73K 15576284
40. BD Kahan P Keown GA Levy A Johnston 2002 Therapeutic drug monitoring of immunosuppressant drugs in clinical practice Clin Ther 24 330 350 1:CAS:528:DC%2BD38XjsV2jsbc%3D 11952020 discussion 329
41. MH Ensom TK Chang P Patel 2001 Pharmacogenetics: the therapeutic drug monitoring of the future? Clin Pharmacokinet 40 783 802 1:CAS:528: DC%2BD3MXpt1ejt7w%3D 11735602
42. AD Askanase DJ Wallace MH Weisman CE Tseng L Bernstein HM Belmont E Seidman M Ishimori PM Izmirly JP Buyon 2009 Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus J Rheumatol 36 89 95 1:CAS:528:DC%2BD1MXit1Cmsbc%3D 19040311
43. E Jaquenoud Sirot JW van der Velden K Rentsch CB Eap P Baumann 2006 Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance Drug Saf 29 735 768 16944962
44. M Sattler FP Guengerich CH Yun U Christians KF Sewing 1992 Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat Drug Metab Dispos 20 753 761 1:CAS:528:DyaK38XmtVCmsr8%3D 1385058
45. E Thervet D Anglicheau B King MH Schlageter B Cassinat P Beaune C Legendre AK Daly 2003 Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients Transplantation 76 1233 1235 1:CAS:528:DC%2BD3sXosVajsLo%3D 14578760
46. DA Hesselink RH van Schaik IP van der Heiden M van der Werf PJ Gregoor J Lindemans W Weimar T van Gelder 2003 Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 74 245 254 1:CAS:528: DC%2BD3sXmvVKmsbY%3D 12966368
47. V Haufroid M Mourad V Van Kerckhove J Wawrzyniak M De Meyer DC Eddour J Malaise D Lison JP Squifflet P Wallemacq 2004 The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients Pharmacogenetics 14 147 154 1:CAS:528:DC%2BD2cXjt1Kjsrs%3D 15167702
48. M Goto S Masuda T Kiuchi Y Ogura F Oike M Okuda K Tanaka K Inui 2004 CYP3A5 1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation Pharmacogenetics 14 471 478 1:CAS:528:DC%2BD2cXlt1Ckt78%3D 15226679
49. IA MacPhee S Fredericks DW Holt 2005 Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation? Expert Opin Pharmacother 6 2593 2605 1:CAS:528: DC%2BD2MXht1Gks7zE 16316299
50. K Tsuchiya H Gatanaga N Tachikawa K Teruya Y Kikuchi M Yoshino T Kuwahara T Shirasaka S Kimura S Oka 2004 Homozygous CYP2B6 6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens Biochem Biophys Res Commun 319 1322 1326 1:CAS:528:DC%2BD2cXkvVCksr0%3D 15194512
51. KN Utecht JJ Hiles J Kolesar 2006 Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors Am J Health Syst Pharm 63 2340 2348 1:CAS:528:DC%2BD28XhtlensLvM 17106006
52. SH Akbas T Bilgen I Keser M Tuncer L Yucetin O Tosun M Gultekin G Luleci 2006 The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients Transplant Proc 38 1290 1292 1:CAS:528:DC%2BD28XlvFGnurg%3D 16797284
53. M Mourad G Mourad P Wallemacq V Garrigue C Van Bellingen V Van Kerckhove M De Meyer J Malaise DC Eddour D Lison JP Squifflet V Haufroid 2005 Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids Transplantation 80 977 984 1:CAS:528:DC%2BD2MXhtFGhs7fE 16249748
54. H Tada N Tsuchiya S Satoh H Kagaya Z Li K Sato M Miura T Suzuki T Kato T Habuchi 2005 Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients Transplant Proc 37 1730 1732 1:CAS:528:DC%2BD2MXks1Crs78%3D 15919447
55. L Elens A Capron VV Kerckhove J Lerut M Mourad D Lison P Wallemacq V Haufroid 2007 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation Pharmacogenet Genomics 17 873 883 1:CAS:528:DC%2BD2sXhtVKhsb7F 17885626
56. DR Kuypers H de Jonge M Naesens E Lerut K Verbeke Y Vanrenterghem 2007 CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients Clin Pharmacol Ther 82 711 725 1:CAS:528:DC%2BD2sXht1ymu7vF 17495880
57. IA Hauser E Schaeffeler S Gauer EH Scheuermann B Wegner J Gossmann H Ackermann C Seidl B Hocher UM Zanger H Geiger M Eichelbaum M Schwab 2005 ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation J Am Soc Nephrol 16 1501 1511 1:CAS:528:DC%2BD2MXksF2gsbw%3D 15772250
58. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Heng AE, Subra JF, Beaune P, Legendre C (2010) Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 87:721-726
59. RA Koster EC Dijkers DR Uges 2009 Robust, high-throughput LC-MS/MS method for therapeutic drug monitoring of cyclosporine, tacrolimus, everolimus, and sirolimus in whole blood Ther Drug Monit 31 116 125 1:CAS:528: DC%2BD1MXpt1Cisw%3D%3D 19065123
60. CR Yates EY Krynetski T Loennechen MY Fessing HL Tai CH Pui MV Relling WE Evans 1997 Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance Ann Intern Med 126 608 614 1:CAS:528:DyaK2sXivFehur8%3D 9103127
61. L Lennard 2002 TPMT in the treatment of Crohn's disease with azathioprine Gut 51 143 146 1:CAS:528:DC%2BD38Xmtlykt74%3D 12117866
62. A Ansari C Hassan J Duley A Marinaki EM Shobowale-Bakre P Seed J Meenan A Yim J Sanderson 2002 Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease Aliment Pharmacol Ther 16 1743 1750 1:CAS:528:DC%2BD38XotlOhsb0%3D 12269967
63. MC Dubinsky S Lamothe HY Yang SR Targan D Sinnett Y Theoret EG Seidman 2000 Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease Gastroenterology 118 705 713 1:CAS:528: DC%2BD3cXis1ens7w%3D 10734022
64. MC Dubinsky H Yang PV Hassard EG Seidman LY Kam MT Abreu SR Targan EA Vasiliauskas 2002 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease Gastroenterology 122 904 915 1:CAS:528:DC%2BD38XjtFOmtbc%3D 11910342
65. HL McLeod EY Krynetski MV Relling WE Evans 2000 Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia Leukemia 14 567 572 1:CAS:528:DC%2BD3cXivFOhur4%3D 10764140
66. E Schaeffeler C Fischer D Brockmeier D Wernet K Moerike M Eichelbaum UM Zanger M Schwab 2004 Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants Pharmacogenetics 14 407 417 1:CAS:528:DC%2BD2cXlt1Cktrs%3D 15226673
67. D Otterness C Szumlanski L Lennard B Klemetsdal J Aarbakke JO Park-Hah H Iven K Schmiegelow E Branum J O'Brien R Weinshilboum 1997 Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms Clin Pharmacol Ther 62 60 73 1:CAS:528:DyaK2sXlsFWls7g%3D 9246020
68. DP McGovern SP Travis J Duley M Shobowale-Bakre el HR Dalton 2002 Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity Gastroenterology 122 838 839 1:STN:280: DC%2BD387ksVaguw%3D%3D 11878296
69. JW Winter D Gaffney D Shapiro RJ Spooner AM Marinaki JD Sanderson PR Mills 2007 Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease Aliment Pharmacol Ther 25 1069 1077 1:CAS:528:DC%2BD2sXmsFars7s%3D 17439508
70. JF Colombel N Ferrari H Debuysere P Marteau JP Gendre B Bonaz JC Soule R Modigliani Y Touze P Catala C Libersa F Broly 2000 Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy Gastroenterology 118 1025 1030 1:CAS:528:DC%2BD3cXktlaiur8%3D 10833476
71. CA Marra JM Esdaile AH Anis 2002 Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine J Rheumatol 29 2507 2512 12465143
72. M Regueiro H Mardini 2002 Determination of thiopurine methyltransferase genotype or phenotype optimizes initial dosing of azathioprine for the treatment of Crohn's disease J Clin Gastroenterol 35 240 244 1:CAS:528: DC%2BD38Xmsl2ks7g%3D 12192200
73. KT Oh AH Anis SC Bae 2004 Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea Rheumatology (Oxford) 43 156 163 1:CAS:528:DC%2BD2cXms1ehtA%3D%3D
74. ME van den Akker-van Marle D Gurwitz SB Detmar CM Enzing MM Hopkins E Gutierrez de Mesa D Ibarreta 2006 Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe Pharmacogenomics 7 783 792 16886902
75. J Mendelsohn J Baselga 2006 Epidermal growth factor receptor targeting in cancer Semin Oncol 33 369 385 1:CAS:528:DC%2BD28XpsVersLk%3D 16890793 (Pubitemid 44142736)
76. KY Chung J Shia NE Kemeny M Shah GK Schwartz A Tse A Hamilton D Pan D Schrag L Schwartz DS Klimstra D Fridman DP Kelsen LB Saltz 2005 Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 1803 1810 1:CAS:528:DC%2BD2MXjt1Ckuro%3D 15677699
77. L Saltz 2005 Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity? Clin Colorectal Cancer 5 Suppl 2 S98 S100 1:CAS:528:DC%2BD2MXhtlaisL7E 16336755
78. E Dolgin 2009 FDA narrows drug label usage Nature 460 1069 1:CAS:528:DC%2BD1MXhtVGiur%2FL 19713906
79. N Ceze D Ternant F Piller D Degenne N Azzopardi E Dorval H Watier T Lecomte G Paintaud 2009 An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab Ther Drug Monit 31 597 601 1:CAS:528: DC%2BD1MXhtFOhsbfO 19730278
80. E Jabbour J Cortes H Kantarjian 2007 Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias Expert Opin Investig Drugs 16 679 687 1:CAS:528:DC%2BD2sXks1aht7o%3D 17461740
81. A Haouala B Zanolari B Rochat M Montemurro K Zaman MA Duchosal HB Ris S Leyvraz N Widmer LA Decosterd 2009 Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry J Chromatogr B Analyt Technol Biomed Life Sci 877 1982 1996 1:CAS:528:DC%2BD1MXnsl2htrY%3D 19505856
82. E Gupta TM Lestingi R Mick J Ramirez EE Vokes MJ Ratain 1994 Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea Cancer Res 54 3723 3725 1:STN:280:DyaK2czgs1ektA%3D%3D 8033091
83. PJ Bosma JR Chowdhury C Bakker S Gantla A de Boer BA Oostra D Lindhout GN Tytgat PL Jansen RP Oude Elferink 1995 The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome N Engl J Med 333 1171 1175 1:CAS:528:DyaK2MXpvF2gs7c%3D 7565971
84. G Monaghan M Ryan R Seddon R Hume B Burchell 1996 Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome Lancet 347 578 581 1:CAS:528:DyaK28XitVGrtrc%3D 8596320
85. L Iyer D Hall S Das MA Mortell J Ramirez S Kim A Di Rienzo MJ Ratain 1999 Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism Clin Pharmacol Ther 65 576 582 1:CAS:528: DyaK1MXjslSrt74%3D 10340924
86. F Innocenti SD Undevia L Iyer PX Chen S Das M Kocherginsky T Karrison L Janisch J Ramirez CM Rudin EE Vokes MJ Ratain 2004 Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan J Clin Oncol 22 1382 1388 1:CAS:528:DC%2BD2cXpt1yjtbk%3D 15007088
87. MG Fakih ME Ross P Starostik 2007 Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities Clin Colorectal Cancer 6 583 587 1:CAS:528:DC%2BD2sXhtVajtLnE 17681105
88. K Sai M Saeki Y Saito S Ozawa N Katori H Jinno R Hasegawa N Kaniwa J Sawada K Komamura K Ueno S Kamakura M Kitakaze Y Kitamura N Kamatani H Minami A Ohtsu K Shirao T Yoshida N Saijo 2004 UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer Clin Pharmacol Ther 75 501 515 1:CAS:528:DC%2BD2cXkslWmtrc%3D 15179405
89. K Araki K Fujita Y Ando F Nagashima W Yamamoto H Endo T Miya K Kodama M Narabayashi Y Sasaki 2006 Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer Cancer Sci 97 1255 1259 1:CAS:528:DC%2BD28XhtFemtbbN 16965601
90. Y Ando K Fujita Y Sasaki Y Hasegawa 2007 UGT1AI 6 and UGT1A1 27 for individualized irinotecan chemotherapy Curr Opin Mol Ther 9 258 262 1:CAS:528:DC%2BD2sXotV2gtbY%3D 17608024
91. SR Jada R Lim CI Wong X Shu SC Lee Q Zhou BC Goh B Chowbay 2007 Role of UGT1A16, UGT1A128 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients Cancer Sci 98 1461 1467 1:CAS:528:DC%2BD2sXhtVaksrvF 17627617
92. MJ Ratain 2006 From bedside to bench to bedside to clinical practice: an odyssey with irinotecan Clin Cancer Res 12 1658 1660 16551845
93. X Wu JR Hawse M Subramaniam MP Goetz JN Ingle TC Spelsberg 2009 The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells Cancer Res 69 1722 1727 1:CAS:528:DC%2BD1MXisFSrtr8%3D 19244106
94. Z Desta BA Ward NV Soukhova DA Flockhart 2004 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6 J Pharmacol Exp Ther 310 1062 1075 1:CAS:528:DC%2BD2cXnt1eqtb0%3D 15159443
95. Y Jin Z Desta V Stearns B Ward H Ho KH Lee T Skaar AM Storniolo L Li A Araba R Blanchard A Nguyen L Ullmer J Hayden S Lemler RM Weinshilboum JM Rae DF Hayes DA Flockhart 2005 CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment J Natl Cancer Inst 97 30 39 1:CAS:528:DC%2BD2MXisVaqsw%3D%3D 15632378
96. S Borges Z Desta L Li TC Skaar BA Ward A Nguyen Y Jin AM Storniolo DM Nikoloff L Wu G Hillman DF Hayes V Stearns DA Flockhart 2006 Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment Clin Pharmacol Ther 80 61 74 1:CAS:528:DC%2BD28Xms1enu7k%3D 16815318
97. MP Goetz JM Rae VJ Suman SL Safgren MM Ames DW Visscher C Reynolds FJ Couch WL Lingle DA Flockhart Z Desta EA Perez JN Ingle 2005 Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes J Clin Oncol 23 9312 9318 1:CAS:528:DC%2BD28Xnt1ynuw%3D%3D 16361630
98. P Wegman S Elingarami J Carstensen O Stal B Nordenskjold S Wingren 2007 Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Breast Cancer Res 9 R7 17244352
99. MP Goetz SK Knox VJ Suman JM Rae SL Safgren MM Ames DW Visscher C Reynolds FJ Couch WL Lingle RM Weinshilboum EG Fritcher AM Nibbe Z Desta A Nguyen DA Flockhart EA Perez JN Ingle 2007 The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen Breast Cancer Res Treat 101 113 121 1:CAS:528:DC%2BD2sXisVylsg%3D%3D 17115111
100. MP Goetz A Kamal MM Ames 2008 Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response Clin Pharmacol Ther 83 160 166 1:CAS:528:DC%2BD2sXhsVylt7bN 17882159
101. W Schroth MP Goetz U Hamann PA Fasching M Schmidt S Winter P Fritz W Simon VJ Suman MM Ames SL Safgren MJ Kuffel HU Ulmer J Bolander R Strick MW Beckmann H Koelbl RM Weinshilboum JN Ingle M Eichelbaum M Schwab H Brauch 2009 Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen JAMA 302 1429 1436 1:CAS:528:DC%2BD1MXht1CksrjO 19809024
102. T Heller J Kirchheiner VW Armstrong H Luthe M Tzvetkov J Brockmoller M Oellerich 2006 AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping Ther Drug Monit 28 673 677 1:CAS:528: DC%2BD28XhtVKrtL3K 17038884
103. Esteve-Romero J, Ochoa-Aranda E, Bose D, Rambla-Alegre M, Peris-Vicente J, Martinavarro-Dominguez A (2010) Tamoxifen monitoring studies in breast cancer patients by micellar liquid chromatography. Anal Bioanal Chem 397:1557-1561
104. MJ Piccart-Gebhart M Procter B Leyland-Jones A Goldhirsch M Untch I Smith L Gianni J Baselga R Bell C Jackisch D Cameron M Dowsett CH Barrios G Steger CS Huang M Andersson M Inbar M Lichinitser I Lang U Nitz H Iwata C Thomssen C Lohrisch TM Suter J Ruschoff T Suto V Greatorex C Ward C Straehle E McFadden MS Dolci RD Gelber 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 1:CAS:528:DC%2BD2MXhtFansr3L 16236737 (Pubitemid 41464705)
105. EH Romond EA Perez J Bryant VJ Suman E GC Jr NE Davidson E Tan-Chiu S Martino S Paik PA Kaufman SM Swain TM Pisansky L Fehrenbacher LA Kutteh VG Vogel DW Visscher G Yothers RB Jenkins AM Brown SR Dakhil EP Mamounas WL Lingle PM Klein JN Ingle N Wolmark 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 1:CAS:528:DC%2BD2MXhtFansr3F 16236738
106. US Food and Drug Administration (2009) Table of valid genomic biomarkers in the context of approved drug labels. Available at: http://www.fda.gov/Drugs/ ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. Accessed 10/14 2009
107. JA Sparano 2001 Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials Semin Oncol 28 20 27 1:CAS:528: DC%2BD3MXjtFWqsr0%3D 11301371
108. S Beauclair P Formento JL Fischel W Lescaut R Largillier E Chamorey P Hofman JM Ferrero G Pages G Milano 2007 Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity Ann Oncol 18 1335 1341 1:STN:280:DC%2BD2svnsFSjtQ%3D%3D 17693647
109. M Pirmohamed S James S Meakin C Green AK Scott TJ Walley K Farrar BK Park AM Breckenridge 2004 Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients Br Med J 329 15 19 (Pubitemid 38869995)
110. U Yasar E Eliasson ML Dahl I Johansson M Ingelman-Sundberg F Sjoqvist 1999 Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population Biochem Biophys Res Commun 254 628 631 1:CAS:528:DyaK1MXhtVegtrs%3D 9920790
111. M Margaglione D Colaizzo G D'Andrea V Brancaccio A Ciampa E Grandone G Di Minno 2000 Genetic modulation of oral anticoagulation with warfarin Thromb Haemost 84 775 778 1:CAS:528:DC%2BD3cXovFCjs7g%3D 11127854
112. MK Higashi DL Veenstra LM Kondo AK Wittkowsky SL Srinouanprachanh FM Farin AE Rettie 2002 Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy JAMA 287 1690 1698 1:CAS:528:DC%2BD38XisFaru7c%3D 11926893
113. LE Visser M van Vliet RH van Schaik AA Kasbergen PA De Smet AG Vulto A Hofman CM van Duijn BH Stricker 2004 The risk of overanticoagulation in patients with cytochrome P450 CYP2C92 or CYP2C93 alleles on acenocoumarol or phenprocoumon Pharmacogenetics 14 27 33 1:CAS:528:DC%2BD2cXjs1agsL8%3D 15128048 (Pubitemid 38183959)
114. D Voora C Eby MW Linder PE Milligan BL Bukaveckas HL McLeod W Maloney J Clohisy RS Burnett L Grosso SK Gatchel BF Gage 2005 Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype Thromb Haemost 93 700 705 1:CAS:528:DC%2BD2MXjs1ertr4%3D 15841315
115. MJ Rieder AP Reiner BF Gage DA Nickerson CS Eby HL McLeod DK Blough KE Thummel DL Veenstra AE Rettie 2005 Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose N Engl J Med 352 2285 2293 1:CAS:528:DC%2BD2MXksl2ltrk%3D 15930419
116. A Osman C Enstrom K Arbring P Soderkvist TL Lindahl 2006 Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records J Thromb Haemost 4 1723 1729 1:CAS:528:DC%2BD28XpvVGrtb4%3D 16879214
117. MH Rosove WW Grody 2009 Should we be applying warfarin pharmacogenetics to clinical practice? No, not now Ann Intern Med 151 270-3 W95
118. Gage BF, Lesko LJ (2008) Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis 25:45-51
119. S Rost A Fregin V Ivaskevicius E Conzelmann K Hortnagel HJ Pelz K Lappegard E Seifried I Scharrer EG Tuddenham CR Muller TM Strom J Oldenburg 2004 Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 Nature 427 537 541 1:CAS:528:DC%2BD2cXpsFWhtQ%3D%3D 14765194
120. R Loebstein I Dvoskin H Halkin M Vecsler A Lubetsky G Rechavi N Amariglio Y Cohen G Ken-Dror S Almog E Gak 2007 A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance Blood 109 2477 2480 1:CAS:528: DC%2BD2sXnslygsLk%3D 17110455
121. K Chu SM Wu T Stanley DW Stafford KA High 1996 A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism J Clin Invest 98 1619 1625 1:CAS:528:DyaK28XmtVClsrw%3D 8833911
122. J Oldenburg EM Quenzel U Harbrecht A Fregin W Kress CR Muller HJ Hertfelder R Schwaab HH Brackmann P Hanfland 1997 Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy Br J Haematol 98 240 244 1:CAS:528:DyaK2sXltlWlur4%3D 9233593
123. E Shikata I Ieiri S Ishiguro H Aono K Inoue T Koide S Ohgi K Otsubo 2004 Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity Blood 103 2630 2635 1:CAS:528:DC%2BD2cXjtVaks7o%3D 14656880
124. M Wadelius K Sorlin O Wallerman J Karlsson QY Yue PK Magnusson C Wadelius
125. S Marsh HL McLeod 2006 Pharmacogenomics: from bedside to clinical practice Hum Mol Genet 15 Spec No 1 R89 R93 1:CAS:528:DC%2BD28XktlSisrY%3D 16651374
126. A Oates PR Jackson CA Austin KS Channer 1998 A new regimen for starting warfarin therapy in out-patients Br J Clin Pharmacol 46 157 161 1:CAS:528:DyaK1cXlsFCitL0%3D 9723825
127. MB O'Connell PR Kowal CJ Allivato TL Repka 2000 Evaluation of warfarin initiation regimens in elderly inpatients Pharmacotherapy 20 923 930 10939553
128. EA Sconce TI Khan HA Wynne P Avery L Monkhouse BP King P Wood P Kesteven AK Daly F Kamali 2005 The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood 106 2329 2333 1:CAS:528:DC%2BD2MXhtVKqt7%2FL 15947090
129. M Wadelius LY Chen K Downes J Ghori S Hunt N Eriksson O Wallerman H Melhus C Wadelius D Bentley P Deloukas 2005 Common VKORC1 and GGCX polymorphisms associated with warfarin dose Pharmacogenomics J 5 262 270 1:CAS:528: DC%2BD2MXmsVyjs78%3D 15883587
130. M Wadelius LY Chen JD Lindh N Eriksson MJ Ghori S Bumpstead L Holm R McGinnis A Rane P Deloukas 2009 The largest prospective warfarin-treated cohort supports genetic forecasting Blood 113 784 792 1:CAS:528:DC%2BD1MXhtlGhsbc%3D 18574025
131. EA Millican PA Lenzini PE Milligan L Grosso C Eby E Deych G Grice JC Clohisy RL Barrack RS Burnett D Voora S Gatchel A Tiemeier BF Gage 2007 Genetic-based dosing in orthopedic patients beginning warfarin therapy Blood 110 1511 1515 1:CAS:528:DC%2BD2sXhtVSgsb3N 17387222
132. EM Hylek C Evans-Molina C Shea LE Henault S Regan 2007 Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation 115 2689 2696 1:CAS:528: DC%2BD2sXlsVOns7o%3D 17515465
133. Miao L, Yang J, Huang C, Shen Z (2007) Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 63:1135-1141
134. International Warfarin Pharmacogenetics Consortium TE Klein RB Altman N Eriksson BF Gage SE Kimmel MT Lee NA Limdi D Page DM Roden MJ Wagner MD Caldwell JA Johnson 2009 Estimation of the warfarin dose with clinical and pharmacogenetic data N Engl J Med 360 753 764 19228618
135. F Takeuchi R McGinnis S Bourgeois C Barnes N Eriksson N Soranzo P Whittaker V Ranganath V Kumanduri W McLaren L Holm J Lindh A Rane M Wadelius P Deloukas 2009 A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose PLoS Genet 5 e1000433 19300499
136. E Phillips S Mallal 2007 Drug hypersensitivity in HIV Curr Opin Allergy Clin Immunol 7 324 330 17620824
137. S Hetherington S McGuirk G Powell A Cutrell O Naderer B Spreen S Lafon G Pearce H Steel 2001 Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir Clin Ther 23 1603 1614 1:CAS:528:DC%2BD3MXptVKrtrc%3D 11726000
138. H Peyriere V Guillemin A Lotthe V Baillat J Fabre C Favier N Atoui S Hansel D Hillaire-Buys J Reynes 2003 Reasons for early abacavir discontinuation in HIV-infected patients Ann Pharmacother 37 1392 1397 1:CAS:528: DC%2BD3sXotl2lt74%3D 14519040
139. S Mallal D Nolan C Witt G Masel AM Martin C Moore D Sayer A Castley C Mamotte D Maxwell I James FT Christiansen 2002 Association between presence of HLA-B 5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir Lancet 359 727 732 1:CAS:528: DC%2BD38XhvVWhsbY%3D 11888582
140. S Hetherington AR Hughes M Mosteller D Shortino KL Baker W Spreen E Lai K Davies A Handley DJ Dow ME Fling M Stocum C Bowman LM Thurmond AD Roses 2002 Genetic variations in HLA-B region and hypersensitivity reactions to abacavir Lancet 359 1121 1122 1:CAS:528:DC%2BD38Xis1ehsLw%3D 11943262
141. DA Hughes FJ Vilar CC Ward A Alfirevic BK Park M Pirmohamed 2004 Cost-effectiveness analysis of HLA B 5701 genotyping in preventing abacavir hypersensitivity Pharmacogenetics 14 335 342 15247625
142. AR Hughes M Mosteller AT Bansal K Davies SA Haneline EH Lai K Nangle T Scott WR Spreen LL Warren AD Roses 2004 Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations Pharmacogenomics 5 203 211 1:CAS:528:DC%2BD2cXivFantb4%3D 15016610
143. A Lucas D Nolan S Mallal 2007 HLA-B 5701 screening for susceptibility to abacavir hypersensitivity J Antimicrob Chemother 59 591 593 1:CAS:528: DC%2BD2sXltVKhur4%3D 17317695
144. AM Martin D Nolan S Gaudieri CA Almeida R Nolan I James F Carvalho E Phillips FT Christiansen AW Purcell J McCluskey S Mallal 2004 Predisposition to abacavir hypersensitivity conferred by HLA-B 5701 and a haplotypic Hsp70-Hom variant Proc Natl Acad Sci USA 101 4180 4185 1:CAS:528:DC%2BD2cXivFart7w%3D 15024131
145. A Rauch D Nolan A Martin E McKinnon C Almeida S Mallal 2006 Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study Clin Infect Dis 43 99 102 1:CAS:528:DC%2BD28XntVKns74%3D 16758424
146. I Reeves D Churchill M Fisher 2006 Screening for HLA-B 5701 reduces the frequency of abacavir hypersensitivity reactions Antivir Ther 11 S1 S192
147. AG Cutrell JE Hernandez JW Fleming MT Edwards MA Moore CH Brothers TR Scott 2004 Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir Ann Pharmacother 38 2171 2172 15536137
148. E Hammond CA Almeida C Mamotte D Nolan E Phillips TA Schollaardt MJ Gill JB Angel D Neurath J Li T Giulivi C McIntyre G Koultchitski B Wong M Reis A Rachlis DE Cole CB Chew S Neifer R Lalonde M Roger A Jeanneau S Mallal 2007 External quality assessment of HLA-B5701 reporting: an international multicentre survey Antivir Ther 12 1027 1032 1:CAS:528:DC%2BD2sXhsVGrt77J 18018760
149. J Donnerer M Kronawetter A Kapper I Haas HH Kessler 2003 Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir Pharmacology 69 197 204 1:CAS:528:DC%2BD3sXptVWktbc%3D 14624060
150. J Donnerer BJ Haas HH Kessler 2008 Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir Pharmacology 82 287 292 1:CAS:528:DC%2BD1cXhtl2qtbfL 18931536
151. J van Lunzen 2007 How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection Eur J Med Res 12 435 440 17933725
152. MC Mueller JR Bogner 2007 Treatment with CCR5 antagonists: which patient may have a benefit? Eur J Med Res 12 441 452 1:CAS:528:DC%2BD2sXhsVGitb%2FJ 17933726
153. T Lorenzen A Stoehr I Walther A Plettenberg 2007 CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1 Eur J Med Res 12 419 425 1:CAS:528:DC%2BD2sXhsVGitb%2FO 17933723
154. A D'Avolio M Simiele L Baietto M Siccardi M Sciandra S Patanella S Bonora G Di Perri 2010 A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients Ther Drug Monit 32 86 92 20040898
155. A Fayet A Beguin B Zanolari S Cruchon N Guignard A Telenti M Cavassini HF Gunthard T Buclin J Biollaz B Rochat LA Decosterd 2009 A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: raltegravir, maraviroc, darunavir, and etravirine J Chromatogr B Anal Technol Biomed Life Sci 877 1057 1069 1:CAS:528:DC%2BD1MXktFahu7w%3D
156. M Rotger S Colombo H Furrer G Bleiber T Buclin BL Lee O Keiser J Biollaz L Decosterd A Telenti 2005 Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients Pharmacogenet Genomics 15 1 5 1:CAS:528: DC%2BD2MXitl2kurg%3D 15864119
157. DW Haas LM Smeaton RW Shafer GK Robbins GD Morse L Labbe GR Wilkinson DB Clifford RT D'Aquila V De Gruttola RB Pollard TC Merigan MS Hirsch L GA Jr JP Donahue RB Kim 2005 Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an adult aids clinical trials group study J Infect Dis 192 1931 1942 1:CAS:528:DC%2BD2MXhtlSrtLrM 16267764
158. DW Haas HJ Ribaudo RB Kim C Tierney GR Wilkinson RM Gulick DB Clifford T Hulgan C Marzolini EP Acosta 2004 Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trials group study AIDS 18 2391 2400 1:CAS:528:DC%2BD2cXhtFGhtbvI 15622315
159. C Nyakutira D Roshammar E Chigutsa P Chonzi M Ashton C Nhachi C Masimirembwa 2008 High prevalence of the CYP2B6 516G->T(6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe Eur J Clin Pharmacol 64 357 365 1:CAS:528:DC%2BD1cXisFCmt78%3D 18057928
160. J Martin G Deslandes E Dailly C Renaud V Reliquet F Raffi P Jolliet 2009 A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV J Chromatogr B Anal Technol Biomed Life Sci 877 3072 3082 1:CAS:528:DC%2BD1MXhtFams7vE
161. ML Dahl F Sjoqvist 2000 Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics Ther Drug Monit 22 114 117 1:CAS:528:DC%2BD3cXhtlajtL4%3D 10688272
162. J Kirchheiner K Nickchen M Bauer ML Wong J Licinio I Roots J Brockmoller 2004 Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response Mol Psychiatry 9 442 473 1:CAS:528:DC%2BD2cXjsV2nu70%3D 15037866
163. E Lessard MA Yessine BA Hamelin G O'Hara J LeBlanc J Turgeon 1999 Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans Pharmacogenetics 9 435 443 1:CAS:528:DyaK1MXmtlGjsrY%3D 10780263
164. ME Shams B Arneth C Hiemke A Dragicevic MJ Muller R Kaiser K Lackner S Hartter 2006 CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine J Clin Pharm Ther 31 493 502 1:CAS:528:DC%2BD28XhtF2mu7rK 16958828
165. L Noehr-Jensen ST Zwisler F Larsen SH Sindrup P Damkier F Nielsen K Brosen 2009 Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker Eur J Clin Pharmacol 65 887 894 1:CAS:528:DC%2BD1MXhtVehu77P 19404631
166. C Kawanishi S Lundgren H Agren L Bertilsson 2004 Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study Eur J Clin Pharmacol 59 803 807 1:CAS:528:DC%2BD2cXovVGltQ%3D%3D 14652703
167. A Gaedigk SD Simon RE Pearce LD Bradford MJ Kennedy JS Leeder 2008 The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype Clin Pharmacol Ther 83 234 242 1:STN:280: DC%2BD1c%2FkslCqug%3D%3D 17971818
168. H Stefansson D Rujescu S Cichon OP Pietilainen A Ingason S Steinberg R Fossdal E Sigurdsson T Sigmundsson JE Buizer-Voskamp T Hansen KD Jakobsen P Muglia C Francks PM Matthews A Gylfason BV Halldorsson D Gudbjartsson TE Thorgeirsson A Sigurdsson A Jonasdottir A Jonasdottir A Bjornsson S Mattiasdottir T Blondal M Haraldsson BB Magnusdottir I Giegling HJ Moller A Hartmann KV Shianna D Ge AC Need C Crombie G Fraser N Walker J Lonnqvist J Suvisaari A Tuulio-Henriksson T Paunio T Toulopoulou E Bramon M Di Forti R Murray M Ruggeri E Vassos S Tosato M Walshe T Li C Vasilescu TW Muhleisen AG Wang H Ullum S Djurovic I Melle J Olesen LA Kiemeney B Franke GROUP C Sabatti NB Freimer JR Gulcher U Thorsteinsdottir A Kong OA Andreassen RA Ophoff A Georgi M Rietschel T Werge H Petursson DB Goldstein MM Nothen L Peltonen DA Collier D St Clair K Stefansson 2008 Large recurrent microdeletions associated with schizophrenia Nature 455 232 236 1:CAS:528:DC%2BD1cXhtV2qtL%2FL 18668039
169. AC Need D Ge ME Weale J Maia S Feng EL Heinzen KV Shianna W Yoon D Kasperaviciute M Gennarelli WJ Strittmatter C Bonvicini G Rossi K Jayathilake PA Cola JP McEvoy RS Keefe EM Fisher PL St Jean I Giegling AM Hartmann HJ Moller A Ruppert G Fraser C Crombie LT Middleton D St Clair AD Roses P Muglia C Francks D Rujescu HY Meltzer DB Goldstein 2009 A genome-wide investigation of SNPs and CNVs in schizophrenia PLoS Genet 5 e1000373 19197363
170. I Grossman PF Sullivan N Walley Y Liu JR Dawson C Gumbs A Gaedigk JS Leeder JP McEvoy ME Weale DB Goldstein 2008 Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study Genet Med 10 720 729 1:CAS:528:DC%2BD1cXht1Cqtr3N 18813134
171. W Hammer F Sjoqvist 1967 Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds Life Sci 6 1895 1903 1:CAS:528:DyaF2sXltFGnu7k%3D 6052684
172. R Mandrioli GC Forti MA Raggi 2006 Fluoxetine metabolism and pharmacological interactions: the role of cytochrome p450 Curr Drug Metab 7 127 133 1:CAS:528:DC%2BD28Xht1Oms74%3D 16472103
173. U Klotz 2007 The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications Clin Pharmacokinet 46 271 279 1:CAS:528:DC%2BD2sXlt1Grsro%3D 17375979
174. GD Anderson 2008 Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs Ther Drug Monit 30 173 180 1:CAS:528:DC%2BD1cXjslSqtbw%3D 18367977
175. W Loscher U Klotz F Zimprich D Schmidt 2009 The clinical impact of pharmacogenetics on the treatment of epilepsy Epilepsia 50 1 23 18627414
176. RS Kidd TB Curry S Gallagher T Edeki J Blaisdell JA Goldstein 2001 Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin Pharmacogenetics 11 803 808 1:CAS:528:DC%2BD38XnsFKqs74%3D 11740344
177. R Brandolese MG Scordo E Spina M Gusella R Padrini 2001 Severe phenytoin intoxication in a subject homozygous for CYP2C93 Clin Pharmacol Ther 70 391 394 1:STN:280:DC%2BD3MrmslSgsQ%3D%3D 11673755
178. R Kerb AS Aynacioglu J Brockmoller R Schlagenhaufer S Bauer T Szekeres A Hamwi M Fritzer-Szekeres C Baumgartner HZ Ongen P Guzelbey I Roots U Brinkmann 2001 The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels Pharmacogenomics J 1 204 210 1:CAS:528: DC%2BD3MXosV2gsLw%3D 11908757
179. CC Hung CJ Lin CC Chen CJ Chang HH Liou 2004 Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms Ther Drug Monit 26 534 540 1:CAS:528:DC%2BD2cXnslelsbo%3D 15385837
180. C Wilson S Schulz SA Waldman 2007 Biomarker development, commercialization, and regulation: individualization of medicine lost in translation Clin Pharmacol Ther 81 153 155 1:STN:280:DC%2BD2s%2FlsFektw%3D%3D 17259939
181. AP Chiang AJ Butte 2009 Data-driven methods to discover molecular determinants of serious adverse drug events Clin Pharmacol Ther 85 259 268 1:CAS:528:DC%2BD1MXit1Ogtbk%3D 19177064
182. M Ingelman-Sundberg 2004 Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future Trends Pharmacol Sci 25 193 200 1:CAS:528:DC%2BD2cXivVGjtro%3D 15063083
183. G Liao X Zhang DJ Clark G Peltz 2008 A genomic "roadmap" to "better" drugs Drug Metab Rev 40 225 239 1:CAS:528: DC%2BD1cXnsVyqs7c%3D 18464044
184. DC Dolinoy RL Jirtle 2008 Environmental epigenomics in human health and disease Environ Mol Mutagen 49 4 8 1:CAS:528:DC%2BD1cXhtlWhs7s%3D 18172876
185. A Gomez M Ingelman-Sundberg 2009 Pharmacoepigenetics: its role in interindividual differences in drug response Clin Pharmacol Ther 85 426 430 1:CAS:528:DC%2BD1MXjtlSmtbY%3D 19242404
186. RS Epstein FW Frueh D Geren D Hummer S McKibbin S O'Connor G Randhawa B Zelman 2009 Payer perspectives on pharmacogenomics testing and drug development Pharmacogenomics 10 149 151 19102724
187. WG Feero AE Guttmacher FS Collins 2008 The genome gets personal-almost JAMA 299 1351 1352 1:CAS:528:DC%2BD1cXjsFSjtLk%3D 18349096